Helius Medical Technologies, Inc. Stock News

NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2021.

NEWTOWN, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today anno

-- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million --

Helius Medical Technologies, Inc. (NASDAQ:HSDT) CEO Dane Andreeff purchased 5,100 shares of the firms stock in a transaction on Friday, December 17th. The stock was bought at an average price of $5.25 per share, for a total transaction of $26,775.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through []

NEWTOWN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today anno

Helius Medical Technologies (NASDAQ:HSDT) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Friday, Zacks.com reports. According to Zacks, Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device called []

Helius Medical Technologies (NASDAQ:HSDT) and ADM Tronics Unlimited (OTCMKTS:ADMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Valuation and Earnings This table compares Helius Medical Technologies and ADM Tronics Unlimiteds []

-- PoNS ® to be used in study of cranial-nerve non-invasive neuromodulation and dynamic gait balance in stroke patients -- -- Collaboration will inform Helius’s registrational program in stroke --

-- PoNS ® to be used in study of cranial-nerve non-invasive neuromodulation and dynamic gait balance in stroke patients -- -- Collaboration will inform Helius''s registrational program in stroke -- NEWTOWN, Pa., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT ) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced its partnership with Dr. Steve Kautz, on an investigator-initiated study, conducted at the Medical University of South Carolina ("MUSC"), to evaluate cranial-nerve non-invasive neuromodulation ("CN-NINM") and dynamic balance in chronic stroke survivors. As part of the study, some patients will receive CN-NINM, which will be delivered using PoNS therapy. "Falls are a major post-stroke complication and developing an optimal rehabilitation program to improve dynamic balance is critical for reducing stroke related morbidity and economic burdens," stated Steve Kautz, Ph.D., Chair, Department of Health Sciences and Research, College of Health Professions, MUSC. "Our study aims to evaluate the effects of PoNS therapy on the recovery of gait and postural stability and, in teaming with Helius, we hope to provide a framework for an innovative rehabilitation protocol." "MUSC is at the forefront of research in rehabilitation for stroke and other disabling neurologic conditions and we are delighted to support this pilot trial in stroke with our PoNS devices," said Antonella Favit-Van Pelt, M.D., Ph.D., Helius'' Chief Medical Officer. "Now that the FDA has granted Breakthrough Designation to PoNS for the treatment of dynamic gait and balance deficits in patients with stroke, this collaboration will provide important information to inform our clinical research and upcoming registrational program, allowing us to observe the functional outcomes of PoNS therapy in stroke patients in a real-world clinical setting.

Helius Medical Technologies (NASDAQ:HSDT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Tuesday, Zacks.com reports. The brokerage currently has a $6.25 price target on the stock. Zacks Investment Researchs target price points to a potential upside of 13.64% from the companys current price. According []

Patent Readies Company for Next Generation of PoNS Therapy Patent Readies Company for Next Generation of PoNS Therapy

Patent Readies Company for Next Generation of PoNS Therapy Patent Readies Company for Next Generation of PoNS Therapy

Zacks Investment Research lowered shares of Helius Medical Technologies (NASDAQ:HSDT) from a buy rating to a hold rating in a research note released on Friday morning, Zacks.com reports. According to Zacks, “Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device […]

Helius Medical Technologies (NASDAQ:HSDT) and ADM Tronics Unlimited (OTCMKTS:ADMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability. Valuation and Earnings This table compares Helius Medical Technologies and ADM Tronics Unlimiteds []

Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis Dr. Favit-Van Pelt will present research that le